[8-K] Nutex Health Inc. Reports Material Event

Rhea-AI Filing Summary

Nutex Health Inc. (NASDAQ: NUTX) filed an 8-K reporting the imminent departure of Chief Operating Officer Joshua DeTillio. Mr. DeTillio notified the company on July 8, 2025 that he will resign effective August 8, 2025 to accept a chief executive role elsewhere. The filing states that his resignation is not related to any disagreement with Nutex Health’s operations, policies, or practices. The Board of Directors has begun a comprehensive search for a successor. No other management or financial information was disclosed in this report.

Positive

• None.

Negative

• COO resignation creates a leadership gap that could hinder operational execution until a qualified successor is onboarded.

Insights

Healthcare Sector Analyst

TL;DR: Key operating executive exits; limited immediate financial impact but raises execution risk.

COO departures can disrupt day-to-day operations, particularly for a multi-facility healthcare provider still scaling its platform. While the company states there is no disagreement and has launched a search, investors will watch closely for delays in strategic initiatives and additional turnover signals. The absence of financial or operational guidance update suggests no direct hit to 2025 outlook, yet succession clarity will be critical for confidence.

0001479681FALSE00014796812025-07-082025-07-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 11, 2025 (July 8, 2025)

NUTEX HEALTH INC.

(Exact name of registrant as specified in its charter)

Delaware			001-41346			11-3363609
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(I.R.S. Employer Identification Number)

6030 S. Rice Ave, Suite C, Houston, Texas 77081

(Address of principal executive offices) (zip code)

(713) 660-0557

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbols(s)			Name of each exchange on which registered
Common Stock, $0.001 par value			NUTX			NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 8, 2025, Joshua DeTillio, the Chief Operating Officer of Nutex Health, Inc. (the “Company”), informed the Company of his decision to resign from his position with the Company effective August 8, 2025, to assume a chief executive officer position at another company. Mr. DeTillio’s decision to resign is not the result of any dispute or disagreement with the Company, the Company's management or the Board of Directors of the Company on any matter relating to the Company's operations, policies or practices.

The Company's Board of Directors is conducting a comprehensive search for potential candidates to replace Mr. DeTillio.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.			Description of Exhibit
104			Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: July 11, 2025

Nutex Health Inc.

By: /s/ Jon C. Bates

Jon C. Bates

Chief Financial Officer

FAQ

When is Nutex Health’s COO Joshua DeTillio leaving?

August 8, 2025 is the effective date of his resignation.

Why is the Nutex Health COO resigning?

He is departing to assume a chief executive officer position at another company; no disputes with NUTX were cited.

Did the filing cite any disagreements between Mr. DeTillio and Nutex Health?

No. The 8-K explicitly states there were no disputes or disagreements regarding company operations or policies.

What actions is Nutex Health taking to replace the COO?

The Board has initiated a comprehensive search for potential candidates to fill the COO role.

Does the 8-K include any updated financial guidance or results?

No. The filing is limited to the executive departure and contains no financial data or guidance updates.